CIBC analyst Kevin Chiang downgrades Canadian National Railway (TSX:CNR) from Outperformer to Neutral and announces C$182 price target.
Analyst Ratings for Rocket Pharmaceuticals
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter: